Actively Recruiting

Phase 1
Phase 2
Age: 2Years - 18Years
All Genders
NCT06635330

Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL

Led by Kara Yakhteh Tajhiz Azma Company · Updated on 2024-10-10

5

Participants Needed

1

Research Sites

174 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this clinical trial is to evaluate the safety and efficacy of CD19 CAR-T cells in pediatric patients of all genders, aged 2 to 18 years, with relapsing or refractory B cell acute lymphoblastic leukemia (r/r B-ALL). The main questions it aims to answer are as following: 1. What is the percentage of patients with overall remission rate (ORR) of complete response (CR) or complete remission with incomplete blood count recovery (CRi)? 2. What is the rate of Event-free survival at first month and 2-3 months after intervention? 3. What is the rate of Overall survival at first month and at 3 months after the intervention?

CONDITIONS

Official Title

Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL

Who Can Participate

Age: 2Years - 18Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Ages 2 to 18 years with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia
  • Disease present in the bone marrow
  • Able to tolerate the apheresis process
  • Life expectancy greater than 12 weeks
  • Lansky or Karnofsky performance score greater than 50%
  • At least 7 days since last chemotherapy and corticosteroid treatment
  • Provided informed consent
  • Has a potential donor for stem cell transplantation
Not Eligible

You will not qualify if you...

  • Active malignancy other than the disease under study
  • Chloroma and leukemic infiltration on MRI or significant neurological symptoms
  • Any central nervous system disorder
  • Presence of active graft versus host disease
  • Radiation therapy within the last 14 days
  • History of Anti-CD19 or Anti-CD20 therapy
  • Donor lymphocyte injection or other cell therapy within the last 30 days
  • Presence of severe active infection
  • Organ dysfunction

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Pediatric cell and gene therapy research center, Children medical center

Tehran, Tehran Province, Iran, 1419733151

Actively Recruiting

Loading map...

Research Team

S

Setayesh Sadeghi

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL | DecenTrialz